Late Systemic Lupus Erythematosus-Associated Insulin Resistance Syndrome: A Rare Cause of De Novo Diabetes Mellitus

Table 3

SLE-associated TBIRS patients’ characteristics.

Clinical and demographic characteristics	Mean and frequencies
Race	African American 39%; Caucasian 16%; Asian 39%; Latin 6%
Age	Mean: 43 years; Range: 8–69 years
Hypoglycemia	35%
Acanthosis	61%
Hypocomplementemia	39%
Late onset lupus (≥50 years)	37.5%
ANAs	Speckled: 32%; Homogeneous: 10%; No specification/no report: 58%
Treatment	Steroids: 84%; Rituximab: 26%; Azathioprine: 13%; Mycophenolate: 13%; Immunoglobulin: 10%; Cyclophosphamide: 10%; Methotrexate: 10% cyclosporine: 6%; Bortezomib: 3%
Treatment response	Spontaneous 3.1%; Unknown 17.9%; Remission 80%
Death	10% (4 patients); 2 due to unknown causes; 1 due to P. jirovecii infection; 1 due to motor vehicle accident